News Search Results
Dec 15, 2025, 08:30 ET Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
[email protected] Link Cell Therapies Link Cell Therapies ("Link") is a biotechnology company based in South San Francisco, California that was founded in 2022 by Robbie Majzner, MD and Crystal Mackall, MD at Stanford University.
More news about: Link Cell Therapies
Dec 15, 2025, 08:00 ET Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase
clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced it will participate in the Biotech Showcase in San Francisco, CA, from January 13-15, 2026. This premier event is for private and micro-mid-cap biotechnology companies
More news about: Diakonos Oncology
Dec 15, 2025, 08:00 ET Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables
More news about: Leadgene Biosolutions
Dec 15, 2025, 08:00 ET Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables
More news about: Leadgene Biosolutions
Dec 15, 2025, 08:00 ET Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease
SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase
More news about: Kenai Therapeutics/BIOCOM
Dec 15, 2025, 08:00 ET Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
More news about: Immusoft
Dec 15, 2025, 06:30 ET Polyhydroxyalkanoate (PHA) Market worth $265.2 million by 2030 - Exclusive Report by MarketsandMarkets™
(US), Kaneka Corporation (Japan), Ecomann Biotechnology Co., Ltd. (China), RWDC Industries (Singapore), Bluepha Co., Ltd. (China), Newlight Technologies, Inc. (US), Ningbo Tianan Biologic Materials Co., Ltd. (China), Biomer (Germany), Beijing PhaBuilder Biotechnology Co., Ltd. (China), and TerraVerdae Bioworks
More news about: MarketsandMarkets
Dec 15, 2025, 05:23 ET Healthcare IT Market Set to More Than Double by 2030 Growing at 15.24% CAGR, Reports Mordor Intelligence
tools, bioinformatics platforms), by application (genomics & transcriptomics, proteomics & metabolomics), by end-user (pharmaceutical & biotechnology companies, academics), and geography (North America, Europe, Asia-Pacific, and More).Agilent Technologies, Illumina Inc, PerkinElmer,
More news about: Mordor Intelligence Private Limited
Dec 15, 2025, 05:14 ET Breast Pump Market Set to Grow at an Impressive CAGR of 8.75% Through 2035 | 8.12 USD Billion | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Dec 15, 2025, 05:00 ET Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
IGF-1R therapy for patients with TED.About Minghui PharmaceuticalFounded in 2018, Minghui Pharmaceutical is a near-commercial biotechnology innovator with two complementary growth engines: a robust clinical oncology portfolio built on its proprietary antibody-drug conjugate (ADC) platform
More news about: Minghui Pharmaceutical
Dec 15, 2025, 04:00 ET MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
innovation, and market responsiveness. Its integrated operational model, financial strength, and commitment to sustainable growth exemplify leadership in biotechnology and position it at the forefront of Southeast Asia's transition toward licensed regenerative therapies.Each year, Frost & Sullivan presents
More news about: Frost & Sullivan
Dec 15, 2025, 04:00 ET MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
innovation, and market responsiveness. Its integrated operational model, financial strength, and commitment to sustainable growth exemplify leadership in biotechnology and position it at the forefront of Southeast Asia's transition toward licensed regenerative therapies.Each year, Frost & Sullivan presents
More news about: Frost & Sullivan
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
https://voovmeeting.com/dm/eb7KovQX2hYD.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Dec 15, 2025, 01:28 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Viva Biotech
Dec 15, 2025, 01:06 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Viva Biotech
Dec 14, 2025, 19:22 ET Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001
More news about: Cynata Therapeutics
Dec 13, 2025, 15:57 ET Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
/PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882),
More news about: Swedish Orphan Biovitrum AB
Dec 13, 2025, 15:52 ET Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
/PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882),
More news about: Swedish Orphan Biovitrum AB
Dec 12, 2025, 12:52 ET Rubin Rudman Adds Kristen Skrajewski to Litigation Group
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 12, 2025, 10:30 ET Pharmaceutical Filtration Market worth $21.75 billion by 2030 | MarketsandMarkets™
(US).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Dec 12, 2025, 09:18 ET AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oligonucleotide-based therapies for functional cure of chronic hepatitis B (CHB), today announced full end-of-follow-up (EOF)
More news about: AusperBio Therapeutics Inc.
Dec 12, 2025, 09:00 ET Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits
striving to become trusted partners for global biopharmaceutical R&D enterprises.About KanryBio BiotechnologyWenzhou KanryBio Biotechnology Co., Ltd. ("KanryBio") leverages the robust scientific and technological strengths of the Wenzhou Institute of the Chinese
More news about: Sanyou Bio
Dec 12, 2025, 07:00 ET Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
www.insilico.com.About TaiGen BiotechnologyFounded in 2001 and listed on the Taiwan OTC Market in 2014, TaiGen Biotechnology is a fully integrated pharmaceutical company focused on innovative small-molecule drugs, particularly
More news about: Insilico Medicine
Dec 12, 2025, 07:00 ET Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
CAMBRIDGE, Mass., Dec. 12, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapy for oncology and inflammation & immunology (I&I), today unveiled initial clinical results from
More news about: Marengo Therapeutics